SEARCH

SEARCH BY CITATION

What does this new year hold in store for the community of those involved in headache medicine and research? Will we progress further on the path that leads to the identification of a migraine generator? Will advances in our understanding of the genetics of migraine and other primary headache disorders yield knowledge relevant to diagnosis and management? Will the CGRP antagonists come to rival the triptans in their impact on the treatment of acute migraine? Will the findings from the PREEMPT study stimulate widespread use of botulinum toxin for the suppression of migraine? Will tonabersat provide effective migraine prophylaxis to patients failing what are now the most commonly prescribed oral prophylactic agents? Will we finally see an appreciable increase in the number of migraine sufferers who seek medical attention . . . and subsequently are gratified with the result? Will headache medicine maintain its momentum as an increasingly “viable” medical subspecialty? Many questions . . . and many more undoubtedly to arise as our expanding knowledge reveals new seas of ignorance.

In this the inaugural issue of 2009, we have attempted to provide a dish laced with ingredients to suit all tastes. Paul Durham and his investigative group report their findings from elegant bench research involving tonabersat. Laforet et al examine the long-term use of divalproex sodium/extended release for migraine prophylaxis in the understudied adolescent population. Returning from my first (and highly enjoyable) visit to Brazil and the Brazilian Headache Congress, it is with particular pleasure that I direct the readership's attention to Dr. Vincent's account of the accomplishments of Professor Leao and to the study by Queiroz et al surveying for the prevalence of tension-type headache in that country. Similarly, in their study of migraine in Germany, Radtke et al remind us that Americans are hardly alone in shouldering the public health burden imposed by headache. Several papers address the potential clinical application of the allodynia phenomenon observed in the research setting by Burstein and others, and Dr. Tfelt-Hansen joins with other contributors to consider the persisting therapeutic challenge posed by cluster headache (and described so eloquently by Ray Vaughn, a chronic cluster patient, in the last issue of this journal). And much more . . . 

On behalf of the editorial office, our superb editorial board, our publisher (Wiley-Blackwell), and the American Headache Society, I wish you all a productive and Very Happy New Year.